For the same reasons, patients with T2D and CKD generally have reduced glycosuria, meaning the frequency of mycotic infection is lower in this setting, but it remains higher with SGLT2 inhibition when compared with placebo. This evidence concerns the gene SLC5A2 and chronic kidney disease.